Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology
Shots:
- Celgene to utilize Obsidian’s DDs (Destabilizing Domains) technology for its cell therapy candidates with DD-regulated IL12 or CD40L proteins for oncology indications
- Obsidian will receive an undisclosed upfront in cash and equity and is eligible to receive an undisclosed milestone- plus royalties
- Obsidian’s is developing DDstechnology to regulate expression of immunomodulatory factors- for precise pharmacologic control of the potent acitivity with optimized safety and efficacy in engineered cell therapies
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
